{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "We conducted a randomized and unblinded 2\u00d72 sequential-factorial trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "We conducted a randomized and unblinded 2\u00d72 sequential-factorial trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients (n=180) received 6 mg/kg rATG"
      },
      "Intervention": {
        "score": 2,
        "evidence": "comparing single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG)"
      },
      "Objective": {
        "score": 1,
        "evidence": "We report the long-term safety and efficacy of SD-rATG induction"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Primary endpoints were renal function (abbreviated modification of diet in renal disease) and chronic graft histopathology (Banff)"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 3,
        "evidence": "randomized and unblinded"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Patients (n=180) received 6 mg/kg rATG"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The SD-rATG associated with improved renal function (2-36 months; P <0.001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "fewer infections"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 15,
    "max_score": 25
  },
  "model": "gpt-4o"
}